Amulirafusp alfa
Based on 1 Customer Validation
Amulirafusp alfa (IMM-0306) is a fusion protein of CD20 monoclonal antibody (mAb) with the CD47 binding domain of SIRPα, with human CD20 Kd 2.45 nM and human CD47 Kd 4.91 nM. Amulirafusp alfa binds to CD20 and CD47 on B cells, engages FcɣR, blocks CD47-SIRPα interaction, activates macrophages, NK cells, and complement cascade, mediates phagocytosis and cytotoxicity, inhibits apoptosis of Jurkat-CSR cells, reverses IL-16 tumor-promoting effects, and binds human/cynomolgus CD47 but not mouse/rat CD47. Amulirafusp alfa can be used for the research of hematological malignancies, relapsed or refractory CD20-positive B-cell non-Hodgkin’s lymphoma, relapsed or refractory B-cell non-Hodgkin lymphoma, and activated B-cell-like diffuse large B-cell lymphoma.
For research use only. We do not sell to patients.
- Purity : 99.89%
- CAS No.: 2850355-94-9
- Molecular Weight:174.06 kDa
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
Isotype
Human IgG1 kappa
Recommend Isotype Controls
Species Reactivity
Human
IC50 & Target
MS4A1/CD47[1]
In Vitro
Amulirafusp alfa (0.0001-10000 nM) binds with high affinity to CD47 on Jurkat cells (EC50 = 16.83 nM), CD20 on Raji-CD47KO cells (EC50 = 18.92 nM), and both antigens simultaneously (EC50 = 11.48 nM; EC50 = 0.02462 μg/mL for dual cell binding)[1].
Amulirafusp alfa has higher binding affinity for purified CD20 (2.45 nM) than for purified CD47 (4.91 nM)[1].
Amulirafusp alfa binds to multiple B-cell lymphoma cell lines, human PBMC, and cynomolgus monkey PBMC, shows minimal binding to human RBC (no hemagglutination), and cross-reacts with human and cynomolgus CD47 but not mouse or rat CD47[1].
Amulirafusp alfa significantly inhibits apoptosis of Jurkat-CSR cells via SIRPα/CD47 pathway blockade, with an IC50 of 4.046 nM[1].
Amulirafusp alfa induces potent ADCC, ADCP, and CDC against Raji, Daudi, Jeko-1, Ramos, SU-DHL-4, and SU-DHL-10 B-cell lymphoma cells, with stronger ADCC than rituximab, greater phagocytic activity against lymphoma cells than rituximab, and reduced activity against normal cells[1].
Amulirafusp alfa (10 μg/mL; 30 min) potently induces antibody-dependent cellular phagocytosis of TMD-8 and U-2932 ABC-DLBCL cells in vitro, with efficacy increasing as the effector-to-tumor cell ratio rises[4].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
In Vivo
Amulirafusp alfa (IMM-0306) (5 mg/kg; i.v.; weekly; 4 weeks) achieves 89.98-92.7% tumor growth inhibition in CB17-SCID mice bearing orthotopic Raji xenografts[1].
Amulirafusp alfa (IMM-0306) (1 mg/kg; i.v.; weekly; 4 weeks) reduces tumor bioluminescence intensity in CB17-SCID mice bearing orthotopic Raji-luc xenografts[1].
Amulirafusp alfa (IMM-0306) (2.5 mg/kg; i.v.; Days 2, 4, 6, 9, 11, and 13) exerts dose-dependent antitumor efficacy in ABC-DLBCL xenograft models, with significantly enhanced activity in tumors with high IL-16 expression, reducing mean tumor volume to ~350 mm3 in pre-IL-16-overexpressing U-2932 xenografts by Day 14[4].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:CB17-SCID mice (subcutaneous xenograft via 2×106 Daudi cells inoculation)[1]
-
Dosage:1.5 mg/kg
-
Administration:i.v.; weekly; 3 weeks
-
Result:Achieved 100% complete tumor remission.
-
Animal Model:CB17-SCID mice (orthotopic xenograft via 5×106 Raji cells tail vein inoculation)[1]
-
Dosage:5 mg/kg
-
Administration:i.v.; weekly; 4 weeks
-
Result:Achieved 89.98% tumor growth inhibition.
Achieved 92.7% tumor growth inhibition.
-
Animal Model:CB17-SCID mice (orthotopic xenograft via Raji-luc cells tail vein inoculation)[1]
-
Dosage:1 mg/kg; 3 mg/kg (lenalidomide combination)
-
Administration:i.v.; weekly; 4 weeks; p.o. (lenalidomide on day 0 and days 5-27)
-
Result:Significantly reduced tumor bioluminescence intensity compared to vehicle control.
Reduced tumor bioluminescence intensity to a lower level than amulirafusp alfa monotherapy, lenalidomide monotherapy, and rituximab plus lenalidomide when combined with lenalidomide.
-
Animal Model:NOD SCID (T- and B-lymphocyte dysfunction, low natural killer cell and complement binding capacity)[4]
-
Dosage:2.5 mg/kg
-
Administration:i.v.; Days 2, 4, 6, 9, 11, and 13
-
Result:Reduced mean tumor volume to ~700 mm3 by Day 14 in mice inoculated with empty vector control U-2932 cells, compared to ~1000 mm3 in the control group.
Reduced mean tumor volume to ~350 mm3 by Day 14 in mice inoculated with pre-IL-16-overexpressing U-2932 cells, compared to ~1600 mm3 in the control group.
Exerted a significantly stronger therapeutic effect in pre-IL-16-overexpressing U-2932 cell-inoculated mice than in empty vector group mice.
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Gene ID
Accession
Q61735-1 & P11836
Conjugated
Unconjugated
Reconsititution
The product can be reconstituted/diluted with sterile PBS or saline.
Format
-
IgG1-kappa-[PROTEIN]2-in-VH
Application
ELISA, FACS, Functional assay
Verified Bioactivity
-
Immobilized CD47 Protein, Human (HEK293, HY-P78095) can bind Amulirafusp alfa. The ED50 for this effect is 12.90 ng/mL. -
Immobilized CD20/MS4A1 Protein-VLP, Human (HEK293, HY-P78543 ) can bind Amulirafusp alfa, The ED50 for this effect is 346.7 ng/mL.
Chemical Information
-
CAS No. 2850355-94-9
-
Appearance Liquid
-
Molecular Weight 174.06 kDa
-
Color Colorless to light yellow
-
SMILES
[Amulirafusp alfa]
-
Synonyms
IMM-0306
-
Shipping
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Phagocytosis Functional Assay
A phagocytosis functional assay measures the ability of phagocytic cells, such as neutrophils, macrophages, monocytes, or microglia/macrophages, to bind and internalize particulate targets including bacteria, yeast particles, beads, or myelin particles. Fluorescent flow-cytometry assays detect target uptake as fluorescence associated with gated phagocytes, while pH-sensitive dyes such as pHrodo increase signal in acidic phagosomal compartments and therefore preferentially report internalized particles rather than particles remaining outside the cell. Microscopy or high-content imaging can be used to confirm intracellular localization and, in some protocols, to follow uptake kinetics.
-
Apoptosis
Apoptosis, also called programmed cell death, is generally characterized by distinct morphological characteristics.
-
TUNEL staining for apoptotic DNA fragmentation
TUNEL staining detects DNA strand breaks by using terminal deoxynucleotidyl transferase to add labeled nucleotides to exposed 3′-OH DNA termini, generating either microscopic staining in fixed cells or tissue sections, or fluorescence/cytometric signal in cell suspensions. TUNEL positivity reflects DNA fragmentation but should not be interpreted alone as definitive apoptosis, because TUNEL can also label necrotic, autolytic, mechanically damaged, or DNA-repair-associated DNA breaks.
-
Cell Cytotoxicity Assay
Cytotoxicity assays are usually based on the assessment of cell membrane damage, which can also be indirectly detected by measuring cell viability. Detection methods include MTT assay, CKK-8 assay, LDH assay and ATP assay, etc.
-
Mammalian live/dead viability and cytotoxicity staining
Live/dead viability and cytotoxicity staining assays are based on the simultaneous detection of intracellular esterase activity in metabolically active (viable) cells and membrane integrity loss in non-viable cells. In commonly used dual-staining approaches, membrane-permeant fluorogenic substrates are converted by intracellular esterases into fluorescent products in live cells, while impermeant DNA-binding dyes selectively enter cells with compromised plasma membranes and label nucleic acids in dead or dying cells, enabling discrimination between viable and non-viable populations by fluorescence microscopy or flow cytometry.
-
Annexin V plus membrane-impermeant dye apoptosis staining
Annexin V-based apoptosis assays rely on the detection of phosphatidylserine (PS) externalization from the inner leaflet of the plasma membrane to the outer leaflet, an early biochemical hallmark of apoptosis. Fluorescently labeled Annexin V binds PS in a calcium-dependent manner, enabling identification of early apoptotic cells by flow cytometry or fluorescence microscopy. When combined with a membrane-impermeant DNA-binding dye (e. g. , propidium iodide), this approach allows discrimination between viable (Annexin V−/dye−), early apoptotic (Annexin V+/dye−), and late apoptotic or necrotic (Annexin V+/dye+) cell populations by assessing membrane integrity and PS exposure.
-
Apoptosis Solutions
Apoptosis is a regulated, generally non-lytic cell-death pathway that removes unwanted, damaged, infected, or abnormal cells through coordinated morphological changes, caspase activation, DNA fragmentation, and membrane remodeling. The intrinsic apoptosis pathway is controlled mainly by mitochondrial outer membrane permeabilization, BCL-2 family proteins, cytochrome c release, apoptosome formation, caspase-9 activation, and downstream executioner caspase-3/7 activation. The extrinsic apoptosis pathway is initiated by death receptors such as Fas, TNFR, and TRAIL receptors, which recruit adaptor proteins and activate caspase-8 before engaging executioner caspases or mitochondrial amplification through BID cleavage. Apoptosis is linked to many phenotypes, including cancer cell killing, tissue homeostasis, immune regulation, neurodegeneration, infection response, and treatment-induced cytotoxicity; unresolved questions include how apoptosis interacts with necroptosis, pyroptosis, ferroptos
-
Cell Viability Determination by MTT Colorimetric Assay
The following protocol uses the MTT colorimetric assay as a classic literature-established method for assessing cell viability/metabolic activity in cultured mammalian cells. MTT[3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] is reduced by metabolically active cells to a colored formazan product; the amount of formazan is quantified spectrophotometrically and provides an indirect measure of metabolically active viable cells. Importantly, MTT reduction reflects cellular oxidoreductase/metabolic activity rather than an absolute direct count of living cells, so changes in cellular metabolism can alter the signal independently of cell number.
Purity & Documentation
-
Data Sheet (282 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
References
[1]. Yu J, et al. IMM0306, a fusion protein of CD20 mAb with the CD47 binding domain of SIRPα, exerts excellent cancer killing efficacy by activating both macrophages and NK cells via blockade of CD47-SIRPα interaction and FcɣR engagement by simultaneously binding to CD47 and CD20 of B cells. Leukemia. 2023 Mar;37(3):695-698. [Content Brief]
[3]. Yang J, et al. Safety and efficacy of amulirafusp alfa (IMM0306), a fusion protein of CD20 monoclonal antibody with the CD47 binding domain of SIRPα, in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: a phase 1/2 study. Journal of hematology & oncology. 2024 Dec 18;17(1):123. [Content Brief]
[4]. Guan X, et al. Lymphoma cell-driven IL-16 is expressed in activated B-cell-like diffuse large B-cell lymphomas and regulates the pro-tumor microenvironment. Haematologica. 2025 Feb 1;110(2):425-438. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)